Performance of apple watch for detecting atrial fibrillation among a known atrial fibrillation population

Jonathan P. Piccini(Clinical Research Institute), Rod Passman(Northwestern University), Jeff Lande, Linda S. Johnson(Boston University), Jagat R. Kanwar(All India Institute of Medical Sciences Bhopal)
European Heart Journal
October 1, 2024
10.1093/eurheartj/ehae666.3538
Cited by 1

Related Papers

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Cryptogenic Stroke and Underlying Atrial Fibrillation
|New England Journal of Medicine|2014|2.2k
Part 8: Adult Advanced Cardiovascular Life Support
|Circulation|2010|1.6k
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
|Kidney International|2011|928
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
|European Heart Journal|2011|614